Best of SABCS® 2024 Early ER Positive Breast Cancer – Dr. Jan-Willem Henning
OR
Chair
Dr. Christine Brezden-Masley
Dr. David Cescon
Speakers
Dr. Jan-Willem Henning
Studies/trials discussed:
- Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
- Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial
- Abstract GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
- Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study
- Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
- Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
